EHC trades 48.9% below Wall Street's consensus target of $146.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes EHC achieves its forward estimates and maintains a stable P/E multiple of 16.3x. This scenario reflects the blended consensus of 26 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Encompass Health Corporation (EHC) has a Wall Street consensus price target of $146.00, based on estimates from 26 covering analysts. With the stock currently trading at $98.03, this represents a potential upside of +48.9%. The company has a market capitalization of $9.75B.
Analyst price targets range from a low of $140.00 to a high of $152.00, representing a 8% spread in expectations. The median target of $146.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 21 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, EHC trades at a trailing P/E of 17.7x and forward P/E of 16.3x. The forward PEG ratio of 1.15 indicates reasonable valuation for growth. Analysts expect EPS to grow -0.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $117.29, with bear and bull scenarios of $73.89 and $154.54 respectively. Model confidence stands at 55/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
USPHU.S. Physical Therapy, Inc. | $964M | $63.32 | $96.00 | +51.6% | Buy | 21.9x | 13 |
SEMSelect Medical Holdings Corporation | $2.1B | $16.54 | $17.75 | +7.3% | Hold | 13.6x | 14 |
ENSGThe Ensign Group, Inc. | $9.0B | $153.65 | $222.33 | +44.7% | Buy | 20.3x | 13 |
ACHCAcadia Healthcare Company, Inc. | $2.3B | $24.87 | $28.33 | +13.9% | Buy | 16.5x | 25 |
UHSUniversal Health Services, Inc. | $8.8B | $141.17 | $216.00 | +53.0% | Hold | 6.0x | 43 |
THCTenet Healthcare Corporation | $15.1B | $172.57 | $259.50 | +50.4% | Buy | 9.6x | 32 |
HCAHCA Healthcare, Inc. | $83.9B | $375.17 | $504.73 | +34.5% | Buy | 12.4x | 46 |
CYHCommunity Health Systems, Inc. | $426M | $3.02 | $2.93 | -3.0% | Hold | — | 37 |
UNHUnitedHealth Group Incorporated | $363.9B | $400.96 | $425.81 | +6.2% | Buy | 21.8x | 52 |
HUMHumana Inc. | $43.3B | $360.65 | $298.50 | -17.2% | Hold | 40.8x | 44 |
Quick answers to the most common questions about buying EHC stock.
The consensus Wall Street price target for EHC is $146, representing 48.9% upside from the current price of $98.03. With 26 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
EHC has a consensus rating of "Buy" based on 26 Wall Street analysts. The rating breakdown is predominantly bullish, with 21 Buy/Strong Buy ratings. The consensus 12-month price target of $146 implies 48.9% upside from current levels.
With a forward P/E of 16.3155x, EHC trades at a relatively low valuation. The consensus target of $146 implies 48.9% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $152 for EHC, while the most conservative target is $140. The consensus of $146 represents the median expectation. Our quantitative valuation model projects a bull case target of $155 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
EHC is heavily covered by Wall Street, with 26 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 20 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month EHC stock forecast based on 26 Wall Street analysts shows a consensus price target of $146, with estimates ranging from $140 (bear case) to $152 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $117, with bear/bull scenarios of $74/$155.
Our quantitative valuation model calculates EHC's fair value at $117 (base case), with a bear case of $74 and bull case of $155. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 55/100.
EHC trades at a forward P/E ratio of 16.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 17.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on EHC, with a "Buy" consensus rating and $146 price target (48.9% upside). 21 of 26 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
EHC analyst price targets range from $140 to $152, a 8% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $146 consensus represents the middle ground. Our model's $74-$155 range provides an independent fundamental perspective.
Deep dive into EHC consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.